Gaeun Kim1, Juyoung Kim1, Yoo Li Lim2,3, Moon Young Kim2,3, Soon Koo Baik4,5. 1. Research Institute for Nursing Science, College of Nursing, Keimyung University, Dalgubeoldae-ro 1095, Dalseo-Gu, Daegu, 704-701, Republic of Korea. 2. Cell Therapy and Tissue Engineering Center, Wonju College of Medicine, Yonsei University, Ilsan-ro 20, Wonju, Gangwon-do, 220-701, Republic of Korea. 3. Department of Internal Medicine, Wonju College of Medicine, Yonsei University, Ilsan-ro 20, Wonju, Gangwon-do, 220-701, Republic of Korea. 4. Cell Therapy and Tissue Engineering Center, Wonju College of Medicine, Yonsei University, Ilsan-ro 20, Wonju, Gangwon-do, 220-701, Republic of Korea. baiksk@yonsei.ac.kr. 5. Department of Internal Medicine, Wonju College of Medicine, Yonsei University, Ilsan-ro 20, Wonju, Gangwon-do, 220-701, Republic of Korea. baiksk@yonsei.ac.kr.
Abstract
BACKGROUND AND AIMS: The renin-angiotensin system (RAS) has an important role in hepatic fibrosis and portal hypertension. RAS inhibitors are already accepted in clinical fields for antihypertensive management, but their effects on hepatic fibrosis are controversial. The aim of this study was to systematically review the effects of RAS inhibitors on hepatic fibrosis based on histological assessment. METHODS: We performed a systematic review and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE, and Cochrane Library databases (up to January 2015) to identify clinical studies evaluating the effects of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on hepatic fibrosis or cirrhosis patients based on histological assessment. Of the 455 studies identified, we analyzed 7, including a total of 1066 patients, which met our selection criteria. RESULTS: According to the MA, patients treated with RAS inhibitors had significantly lower fibrosis scores (SMD -0.68, 95 % CI -1.03, -0.34, I (2) = 0 %, p < 0.0001) and smaller fibrosis areas (SMD -0.80, 95 % CI -1.18, -0.41, I (2) = 0 %, p < 0.0001) than controls. Serum fibrosis markers such as TGF-β1, collagen I, IV, TIMP-1, and MMP2 were significantly reduced in the intervention group. In two studies, mean arterial pressures were significantly decreased in RAS inhibitor users, but there were no reports about symptoms related to decreased blood pressure. No significant difference was found in serum creatinine levels between the intervention and control groups, and significant renal dysfunction was not observed after administration of RAS inhibitors. CONCLUSIONS: RAS inhibitors are potential therapeutic agents for hepatic fibrosis, which can be safely used in patients with chronic liver disease.
BACKGROUND AND AIMS: The renin-angiotensin system (RAS) has an important role in hepatic fibrosis and portal hypertension. RAS inhibitors are already accepted in clinical fields for antihypertensive management, but their effects on hepatic fibrosis are controversial. The aim of this study was to systematically review the effects of RAS inhibitors on hepatic fibrosis based on histological assessment. METHODS: We performed a systematic review and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE, and Cochrane Library databases (up to January 2015) to identify clinical studies evaluating the effects of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on hepatic fibrosis or cirrhosispatients based on histological assessment. Of the 455 studies identified, we analyzed 7, including a total of 1066 patients, which met our selection criteria. RESULTS: According to the MA, patients treated with RAS inhibitors had significantly lower fibrosis scores (SMD -0.68, 95 % CI -1.03, -0.34, I (2) = 0 %, p < 0.0001) and smaller fibrosis areas (SMD -0.80, 95 % CI -1.18, -0.41, I (2) = 0 %, p < 0.0001) than controls. Serum fibrosis markers such as TGF-β1, collagen I, IV, TIMP-1, and MMP2 were significantly reduced in the intervention group. In two studies, mean arterial pressures were significantly decreased in RAS inhibitor users, but there were no reports about symptoms related to decreased blood pressure. No significant difference was found in serum creatinine levels between the intervention and control groups, and significant renal dysfunction was not observed after administration of RAS inhibitors. CONCLUSIONS: RAS inhibitors are potential therapeutic agents for hepatic fibrosis, which can be safely used in patients with chronic liver disease.
Authors: Regina Maria Pereira; Robson Augusto Souza dos Santos; Filipi Leles da Costa Dias; Mauro Martins Teixeira; Ana Cristina Simões e Silva Journal: World J Gastroenterol Date: 2009-06-07 Impact factor: 5.742
Authors: Montserrat Moreno; Teresa Gonzalo; Robbert J Kok; Pau Sancho-Bru; Marike van Beuge; Josine Swart; Jai Prakash; Kai Temming; Constantino Fondevila; Leonie Beljaars; Marie Lacombe; Paul van der Hoeven; Vicente Arroyo; Klaas Poelstra; David A Brenner; Pere Ginès; Ramón Bataller Journal: Hepatology Date: 2010-03 Impact factor: 17.425
Authors: Gaeun Kim; Youn Zoo Cho; Soon Koo Baik; Moon Young Kim; Won Ki Hong; Sang Ok Kwon Journal: Korean J Radiol Date: 2015-02-27 Impact factor: 3.500
Authors: Gaeun Kim; Young Woo Eom; Soon Koo Baik; Yeonghee Shin; Yoo Li Lim; Moon Young Kim; Sang Ok Kwon; Sei Jin Chang Journal: J Korean Med Sci Date: 2015-09-12 Impact factor: 2.153
Authors: Ki Tae Suk; Moon Young Kim; Soung Won Jeong; Jae Young Jang; Yoon Ok Jang; Soon Koo Baik Journal: Dig Dis Sci Date: 2017-12-01 Impact factor: 3.199
Authors: David J Goldberg; Lea F Surrey; Andrew C Glatz; Kathryn Dodds; Michael L O'Byrne; Henry C Lin; Mark Fogel; Jonathan J Rome; Elizabeth B Rand; Pierre Russo; Jack Rychik Journal: J Am Heart Assoc Date: 2017-04-26 Impact factor: 5.501
Authors: Ana Cristina Simões E Silva; Aline S Miranda; Natália P Rocha; Antônio L Teixeira Journal: World J Gastroenterol Date: 2017-05-21 Impact factor: 5.742